Sustained Release Therapeutic Drug Delivery Device (08046)
- 详细技术说明
- KEY BENEFIT: Delivery of lower steady state therapeutic drug doses at the target site to minimize side effects and toxicity.
- *Abstract
-
The University ofLouisville is seeking a company interested in commercializing a novel approach fordelivering therapeutic agents through a drug-entrapped cylindrical polymerdevice implanted subcutaneously and/or at the target site. While these subcutaneous polymeric implantscan be used to deliver drug treatments for a variety of disease conditions, thecurrent key application has been the delivery ofchemo-preventative/chemotherapeutic agents. Conventional methods for chemotherapy agentsgiven orally require high doses, with potential toxicity, for anti-tumoractivity due to their limited bioavailability. To reduce effective dose, increasebioavailability, and minimize or eliminate toxicity, UofL researchers have createda polymeric device for the delivery of steady low doses of therapeutic drugs overa long duration of time.
ADVANTAGES
- The device delivers lower doses over a long duration of time and has the potential to achieve the same efficacy as the traditional oral route, while avoiding the adverse side effects and toxicity of high doses.
- The approach can be readily extended to therapeutic drugs for residual cancer and metastasis.
- The drug implants can be implanted subcutaneously and/or in the target tissue following treatment of primary cancer, thereby potentially preventing and/or delaying the occurrence of secondary cancer(s).
MARKET APPLICATIONS
- Targeted,localized therapy following radiation, chemo, and/or surgery to preventsecondary or residual breast cancers, cervical cancer and other cancers.
- Administration of sustained doses of anti-inflammatory agents before and after treatment with high doses of therapeutic drugs which generally accompany inflammatory responses.
- Preventative therapy for high risk individuals with pre-cancerous conditions and secondary cancers.
- Delivery of therapies for other disease conditions where sustained drug levels are desired, for example, hypertension, high cholesterol levels, seasonal allergies, etc.
TECHNOLOGY
UofL researchers have developed a novel approach ofdelivering chemopreventive/chemotherapeutic agents through subcutaneousbiodegradable polymeric implants entrapped with various compounds. The device has been found effective indelivering sustained low doses. This device was tested in vitro with two natural chemopreventive agents (curcumin andgreen tea polyphenols). In vivo studies with curcumin implantshave also elicited sustained release as well as a chemoprotective response.
INTELLECTUAL PROPERTY
- U.S. Patent Application s/n 12/401,175;Publication no. US2009/0274746; filed Nov. 5, 2009.
- Australia Patent Application 2009/223,653.
- European Patent Application, EP09719335.3.
CONTACT
For additional information, please contact the Office of Technology Transfer:
Telephone: (502) 852-2965
Email: thinker@louisville.edu
Holly Symonds Clark, Interim Co-Director
Website: http://louisville.edu/thinker
Reference Disclosure No. 08046
- 国家/地区
- 美国
